|
credibility check |
| title |
Including E-Cigarettes in the FDA Rule Limiting Nicotine |
| doi |
10.1001/jama.2023.14254 |
| url |
https://doi.org/10.1001/jama.2023.14254 |
| journal |
JAMA |
| authors |
Aaron / Wallace / Sinha |
| tags |
emotive-phrasing, fda-prev, numerology, fictional-premise, hazard-conflation |
|
Note: Phase I scoring is contributor-based, not reviewed.
|
| localScore |
🟨 |
potentialCompetingInterest
| grant-bias | 0.05 | 🟩 |
|---|
| policy-suggestive | 0.9 | 🟪 |
|---|
| profit-healthcare | 0.9 | 🟪 |
|---|
| unratified-treaty | 1 | 🟪 |
|---|
potentialDomainPrior
| regulatory-misdeclaration | 0.5 | 🟧 |
|---|
| conflating-terminology | 0.6 | 🟧 |
|---|
| exaggerative-phrasing | 0.05 | 🟩 |
|---|
| misinformation-prevalence | 0.8 | 🟥 |
|---|
| nicotine-addiction | 0.1 | 🟩 |
|---|
| policy-validation | 0.35 | 🟨 |
|---|
| prohibition-pretext | 0.1 | 🟩 |
|---|
potentialImplicitBias
| zero-risk | 0.4 | 🟨 |
|---|
| kin-liability | 0.25 | 🟨 |
|---|
| preferential-subgroup | 0.85 | 🟪 |
|---|
| stakeholder-disregard | 0.1 | 🟩 |
|---|
studyFindings
| negative | 0.75 | 🟥 |
|---|
| clinical-relevance | 0.4 | 🟨 |
|---|
Tags
- emotive-phrasing
- fda-prev
- numerology
- fictional-premise
- hazard-conflation
Comment
Pigeonholed from legal perspective, hence no consideration to more plausible outcomes (illict market) from barely hypothetical premise. Rationale for expansion onto NVPs is weak. Authors somewhat aware of diff dependency potential. Yet prone to TIC lobbing/scicomm ecosystem. Despite initial appeal to kin liability, the argument about lackluster e-cig vendor self-regulation seems the most genuine motive here. (Unfortunately bungled up in last para).
Article seemingly inattentive to agent of rapid youth smoking decline (solely conceptualizes non-smoking adolescents). Also unmindful about origin of unscientific EU 20mg compromise (predating 4th gen low-plume devices, compensatory use / self-titration, heavy smoker careers / tobacco death reduction; -- almost threw up on the pharmacotherapy superstition).
Mixup of credible references with [10].
Difficult to tell if rooted in nirvancy fallacy, or limited interest in causators for FDAs lethargy. (Lack of advertisment regulation and unintended curiousity snowballing is kinda out of scope though).
Unlikely to be part of the prevalent FUD campaigns, even though using the common percentage numerology. Some authors quite subject-versed [4], even if mirroring MI multiplexers and preponderance in zero-risk bias / appeal to motive.
But overall redeemed per CI disclosure (ya know, given the journal).
Brief notes/asides are encouraged here for initial overviews.
Thus no emphasis placed on legibility or typo absence.